Hodgkin Lymphoma
The latest news, research, and perspectives in Hodgkin lymphoma. Both types of Hodgkin lymphoma, classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma, affect the lymphatic system and advances in diagnosis and treatment have led to high cure rates.
Advertisement
Advertisement
FDG-PET response-guided salvage may identify which pediatric patients achieve excellent outcomes without transplant.
Challenges exist in translating individual patients' risk into risk groups for use in everyday practice or a trial's design.
A phase 2 study sought to determine if use of nivolumab instead of vinblastine in the test combination improved safety.
BrECADD showed better tolerability and efficacy than eBEACOPP for the treatment of advanced-stage classical Hodgkin lymphoma.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
Dr. Nowakowski encourages physicians to refer patients to clinical trials exploring a novel mechanism for CNS lymphoma.
Resistance remains a challenge in central nervous system lymphoma, creating a need for novel therapeutic combinations.
The TakeAim study explores dual inhibition with BTK and IRAK4 inhibitors.
Grzegorz Nowakowski discusses the challenges and advances in central nervous system lymphoma treatment.
David Russler-Germain, MD, PhD, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and CLL.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
Progression-free survival was extended with the use of nivolumab plus the AVD regimen in patients advanced cHL in SWOG S1826.
A significant percentage of patients with advanced cHL treated in the first-line reported tingling in fingers or hands.
The BrECADD regimen led to a notable decrease in the risk of disease progression or death vs BEACOP in patients with AS-cHL.
Andrew Evens, DO, MSc, FACP, discusses tailoring management by patient fitness in this setting plus recent clinical trials.
A phase I clinical trial on IDP-023 is currently enrolling patients.
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
Susan Parsons, MD, MRP; Andrew Evans, DO, MBA, MSc; and Matthew Maurer, DMSc; discuss the HoLISTIC consortium.
Dr. Nastoupil spoke about how the meeting can help clinicians learn how apply knowledge from the latest research.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
Section Editor
Farrukh Awan, MDProfessor, Department of Internal Medicine, UT Southwestern Medical Center
Advertisement
Latest News
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.